Precision Biosciences Inc

NASDAQ:DTIL  
1.47
+0.01 (+0.68%)
Other Pre-Announcement

Precision BioSciences Provides Update On Allogeneic CAR T Programs

Published: 06/08/2022 11:30 GMT
Precision Biosciences Inc (DTIL) - Precision Biosciences Provides Update on Allogeneic Car T Programs and Path Forward With Its Lead Pbcar0191 Candidate for Car T Relapsed Patient Population.
Precision Biosciences -pbcar0191 Achieved Peak Car T Cell Expansion Matching Data From Autologous Car T Peak Expansion in Long Term Durable Responders.
Precision Biosciences Inc - Pbcar19b Car T Cell Manufacturing Optimization Process Completed; Dose Level 2 Expected to Commence in Q3 2022.
Precision Biosciences- Pbcar0191 Achieved 100% Orr, 73% Cr Rate, 50% Durable Response Greater Than 6 Months Among Evaluable Car T Relapsed Subjects.
Precision Biosciences - in Second Half of Year, Plan to Continue Dosing Subjects With Optimized Pbcar0191 in Car T Relapsed Patient Population.
Precision - in Second Half of This Year, We Plan to Continue Dosing Subjects With Optimized Pbcar0191 in This Car T Relapsed Patient Population.
Precision Biosciences - Expect to Request Meeting With FDA to Review Data for Guidance, to Provide Next Update on Pbcar0191 Toward Year End.
Precision Biosciences Inc - Company's Balance of Cash and Cash Equivalents Was Approximately $121 Million As of May 31, 2022.
Precision - Continues to Expect That Existing Cash, Operational Receipts, Available Credit Will Be Sufficient to Fund Requirements Into Mid-2023.